Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04721821 · ClinicalTrials.gov registry record

Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.

A clinical trial, sponsored by Pfizer.

Completed
Registry status
7,807
Enrollment target

NCT04721821 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 7,807 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04721821 has completed, sponsored by Pfizer.

COMPLETED
Registry status
7,807 participants
Enrollment target

Study Summary

This study is to investigate if there has been a shift in treatment with tofacitinib, assessing real world patient data and entered in the Corrona registry between 2016 and 2020.

Interventions

  • DRUG Tofacitinib

Trial Details

FieldValue
Enrollment Target 7,807 participants
Start Date 2021-01-22
Est. Completion 2021-11-29

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT04721821

The ClinicalTrials.gov registry entry for NCT04721821 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7,807 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Tofacitinib is the first listed.

NCT04721821 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04721821 about?

NCT04721821 is a clinical study titled "Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.". This study is to investigate if there has been a shift in treatment with tofacitinib, assessing real world patient data and entered in the Corrona registry between 2016 and 2020.

What is the current status of trial NCT04721821?

This trial is currently completed. The enrollment target is 7,807 participants. The study started on 2021-01-22. Estimated completion is 2021-11-29.

What interventions are being tested in trial NCT04721821?

The interventions under investigation include: Tofacitinib (DRUG).

Who is sponsoring clinical trial NCT04721821?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.